Page last updated: 2024-11-06

tiflucarbine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

tiflucarbine: structure given in first source; calmodulin antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65677
CHEMBL ID2104715
SCHEMBL ID500036
MeSH IDM0143660

Synonyms (18)

Synonym
tiflucarbine
CHEMBL2104715
tiflucarbinum [latin]
6h-pyrido(4,3-b)thieno(3,2-e)indole, 9-ethyl-4-fluoro-7,8,9,10-tetrahydro-1-methyl-
9-ethyl-4-fluoro-7,8,9,10-tetrahydro-1-methyl-6h-pyrido(4,3-b)thieno(3,2-e)indole
tiflucarbina [spanish]
89875-86-5
tiflucarbina
m2108nuy0c ,
unii-m2108nuy0c
tiflucarbine [inn]
tiflucarbinum
SCHEMBL500036
DTXSID90237924
bay-p 4495
Q27283371
14-ethyl-7-fluoro-3-methyl-5-thia-10,14-diazatetracyclo[7.7.0.02,6.011,16]hexadeca-1,3,6,8,11(16)-pentaene
bay- 4495

Research Excerpts

Overview

Tiflucarbine is a structurally novel antidepressant that binds at central serotonin (5-HT) binding sites.

ExcerptReferenceRelevance
"Tiflucarbine is a structurally novel antidepressant that binds at central serotonin (5-HT) binding sites. "( Stimulus properties of tiflucarbine: a novel antidepressant agent.
De Vry, J; Glaser, T; Glennon, RA; Spencer, DG, 1990
)
2.03

Treatment

ExcerptReferenceRelevance
"Tiflucarbine treatment increased the specific activity of soluble calmodulin (CaM)-dependent phosphodiesterase in rat brain."( The potential antidepressant tiflucarbine down-regulates beta-adrenoceptors in rat brain.
Schmidt, BH; Schultz, JE, 1986
)
1.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's5 (83.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]